Blue Cross Blue Shield RI IMRT Coverage Prior Auth

Medical Necessity and Coverage Criteria

Abdomen, Pelvis, Chest — Medical necessity

Abdomen, pelvis and chest: IMRT may be considered medically necessary when specified conditions are met.

Bladder cancer curative intent: Treatment intent is curative AND to treat primary, non-metastatic bladder carcinoma

From Abdomen, Pelvis and Chest criteria

Dosimetric justification for abdomen/pelvis tumors: IMRT may be considered when 3D-CRT planning predicts radiation dose to an adjacent organ would result in unacceptable normal tissue toxicity

Includes hepatobiliary, stomach, pancreas, esophagus, rectal locations, gynecologic tumors

Breast — Medical necessity

Breast: IMRT may be medically necessary under specified conditions.

Whole-breast left-sided post-BCS: As a technique to deliver whole-breast irradiation after breast conserving surgery for left-sided cancer when: IMRT dosimetry demonstrates significantly reduced cardiac exposure AND significant cardiac exposure cannot be avoided using alternative techniques AND target coverage results in cardiac exposure that would be unacceptable with standard techniques OR there is a reduction in absolute heart volume receiving ≥25 Gy by at least 20%>=20% reduction in heart volume receiving 25 Gy

Chunk 4

Whole-breast right-sided post-BCS: For right-sided breast after BCS when 3D conformal planning results in hot spots (dose variation >10%) AND the right breast volume >500 cm3 AND the hot spots can be avoided with IMRTbreast volume >500 cm3; hot spots >10%

Chunk 4

Partial-breast irradiation: IMRT considered for partial-breast irradiation after BCS when accelerated APBI schedules (eg, 10 fractions BID or 5 fractions daily) are used OR when 15–16 fraction IMRT is planned OR when 3D-CRT would result in unacceptable toxicity15-16 fractions or APBI regimens

Chunk 4

Chest wall/regional nodal post-mastectomy or with regional nodal RT: IMRT considered medically necessary for chest wall ± regional nodal irradiation post-mastectomy or after BCS with regional nodal RT when any of the following are present: primary tumor >5 cm OR positive/close surgical margins (<1 mm) OR planned/delivered fractions <28tumor >5 cm; margins <1 mm; <28 fractions

Chunk 5

CNS — Medical necessity

Central nervous system tumors: IMRT may be medically necessary when specified.

Brain tumors near organs at risk: For malignant or benign brain tumors when tumor is proximate to organs at risk (brain stem, spinal cord, cochlea, eye structures including optic nerve and chiasm, lens, retina) AND 3D-CRT planning cannot meet dose-volume constraints for normal tissue tolerance

Chunk 6

Hippocampal-avoiding IMRT for brain metastases: Hippocampal-avoiding IMRT is medically necessary when brain metastases are outside a 5-mm margin around either hippocampus AND expected survival ≥4 months>=4 months survival; >5-mm distance from hippocampus

Chunk 6

Head/Neck/Thyroid — Medical necessity

Head, neck or thyroid: IMRT may be medically necessary for listed head and neck cancers and for thyroid cancers meeting proximity/dosimetric criteria.

Head and neck cancers: IMRT may be considered medically necessary for oral/lip cavity, larynx, oropharynx, hypopharynx, nasopharynx, paranasal sinuses/nasal cavity, salivary glands, and occult primaries in the head and neck region

Chunk 7

Thyroid cancers: IMRT considered when tumor is in close proximity to organs at risk (eg, esophagus, salivary glands, spinal cord) AND when 3D-CRT planning is unable to meet dose-volume constraints for normal tissue tolerance

Chunk 7

Lung — Medical necessity

Lung: IMRT may be medically necessary when ALL criteria are met.

Lung IMRT criteria: Standard 3D conformal planning results in >35% of normal lung receiving >20 Gy (V20) AND radiotherapy is given with curative intent AND IMRT planning demonstrates an absolute reduction in V20 of at least 10% compared with the 3D planBaseline V20 >35% and absolute V20 reduction >=10%

Chunk 8

Prostate — Medical necessity

Prostate: IMRT may be medically necessary for multiple prostate indications.

Localized prostate at specified doses: For definitive treatment of localized prostate cancer at radiation doses of 75.6 to 79.2 Gy75.6-79.2 Gy

Chunk 9

Locally advanced or nodal disease: For locally advanced disease confined to adjacent structures and/or involvement of local lymph nodes

Chunk 9

Post-prostatectomy therapy: Post-prostatectomy radiotherapy: salvage therapy for biochemical or local recurrence without distant metastases OR adjuvant therapy for adverse pathologic findings or persistently detectable PSA after prostatectomy

Chunk 9

Sarcomas — Medical necessity

Sarcomas: IMRT may be medically necessary when ANY listed conditions are met.

Retroperitoneal sarcoma: Initial treatment of a primary retroperitoneal sarcoma

Chunk 10

Extremity sarcoma: Treatment of an extremity sarcoma

Chunk 10

Previously irradiated field: Treatment to a previously irradiated field

Chunk 10

Anal/Anorectal, GI and Gynecologic — Medical necessity and evidence

Anal/anorectal cancers and GI/gynecologic cancers: coverage statements based on evidence.

Anal canal cancer: IMRT may be considered medically necessary as an approach to delivering radiotherapy for individuals with cancer of the anus/anal canal

Chunk 2

Evidence summary GI/gynecologic: Comparative evidence (RCTs, systematic reviews, and nonrandomized studies) demonstrates that IMRT decreases GI toxicity compared with 3D-CRT for anorectal and gynecologic cancers; this toxicity reduction is expected to improve quality of life and net health outcome in selected patients

Chunks 18 and 19

Site-specific coverage rationale (evidence-based findings)

Covered when evidence shows clinical benefit (reduced toxicity or improved outcomes) versus alternative RT techniques for specific tumor sites

Gastrointestinal cancers: Nonrandomized comparative studies, retrospective series, and a systematic review show IMRT decreases GI toxicity versus 3D-CRT in stomach, hepatobiliary, and pancreatic cancers; available evidence suggests improvement in net health outcome

Chunk 18

Gynecologic cancers: Systematic reviews, randomized trials, and comparative studies indicate IMRT reduces GI and GU toxicity versus 3D-CRT; survival is generally comparable and toxicity reduction is expected to improve quality of life

Chunk 18

Anorectal/Anal cancers: Small RCTs and comparative studies demonstrate fewer acute and late GI adverse events with IMRT plus chemotherapy versus 3D-CRT plus chemotherapy, supporting improved net health outcome

Chunk 19

IMRT is not covered for indications that are not specifically listed in the medical criteria section. In addition, IMRT is not covered when used to deliver palliative radiotherapy for individuals with lung cancer.

HCPCS code A4648 (tissue marker; implantable, any type, each) is noted in the coding section and is not separately reimbursed for institutional providers.

For Medicare Advantage Plans (and for Commercial Products where indicated), IMRT is considered not medically necessary for all indications not listed in the medical criteria section; requests for IMRT outside the enumerated, evidence-based indications are not covered and will be denied.

Comparative data versus 3D conformal radiotherapy (3D-CRT) are limited for some settings (for example, whole-breast irradiation). Randomized trials and dosimetry studies show IMRT can reduce acute skin toxicity and improve dose homogeneity versus older techniques, but because whole-breast RT is now commonly delivered by 3D-CRT, those comparative data have limited value in demonstrating routine superiority of IMRT absent a specific dosimetric need.

Billing and Code Lists

Non-reimbursable / device code noteHCPCS

A4648

Tissue marker; implantable, any type, each (Note: This code is not separately reimbursed for institutional providers:)

Covered IMRT planning and delivery codes (Medicare Advantage & Commercial)mixedCovered

77338	Multi-lear collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure tolerance specifications partial
77385	Intensity modulated radiation treatment delivery (IMRT), includes guicance and tracking, when performed; simple (Institutional providers)
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex (Institutional providers)
G6015	Intensity modulated treatment delivery, single Or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session: (Professional providers)

Alternative IMRT delivery code (professional)HCPCSCovered

G6016

Compensator-based beam modulation treatment delivery of inverse planned treatment 3 or more high resolution (milled or cast) compensator; convergent beam modulated fields, per treatment session: (Professional providers)

Prior Authorization, Documentation, and Billing Actions

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products via the online tool for participating providers.

Medicare Advantage: prior authorization required
Commercial Products: prior authorization recommended

Billing Rule

IMRT Codes — Coverage and Documentation

The following IMRT‑related codes are covered for Medicare Advantage Plans and Commercial Products when the medical necessity criteria are met. Ensure documentation supports the medical necessity and is available on request.

77338 — Multi-leaf collimator (MLC) device(s) for IMRT, design and construction per IMRT plan

Background and Context

Intensity-modulated radiotherapy (IMRT) is an advanced planning and delivery technique that uses computer-based inverse planning and multileaf collimators to modulate beam intensity across multiple fields. This modulation improves dose conformity to the target while sparing adjacent normal tissues compared with conventional techniques. Variations of IMRT, including volumetric modulated arc therapy (VMAT), and the use of image guidance can increase delivery efficiency and precision.

Definitions and Key Terms

Intensity-modulated radiotherapy (IMRT) definition

DefinitionIntensity-modulated radiotherapy (IMRT) uses computer-based inverse treatment planning with multileaf collimators (MLCs) and CT/MR imaging to modulate the intensity of multiple overlapping beams across shaped fields to improve dose conformity to the target and spare adjacent normal tissues.

Key componentsComputer optimization of beam locations and intensities based on delineated target, prescribed dose, and normal-tissue dose constraints.

Clinical rationaleIncreased conformality may permit tumor dose escalation without increasing normal tissue toxicity, improving local control and reducing acute and late radiation toxicities.

Planning/delivery characteristicsMore complex, time-consuming, and labor-intensive than 3D-CRT due to inverse planning and MLC shaping of multiple fields.

Volumetric modulated arc therapy (VMAT) definition

OpenPayer

Intensity-Modulated Radiotherapy (IMRT) — Coverage Criteria and Authorization

Medical Necessity and Coverage Criteria

Billing and Code Lists

Prior Authorization, Documentation, and Billing Actions

Background and Context

Definitions and Key Terms